Short-Term GLP-1 Treatment Providers: 9 Picks for a 1-to-6-Month Plan (2026)

By Weight Loss Provider Guide Research Team · Last verified: May 5, 2026 · Editorial policy · Affiliate disclosure

Last updated: May 5, 2026. Next scheduled verification: June 2026.

Weight Loss Provider Guide is an independent comparison resource. If you use our links, we may earn a commission at no extra cost to you. Our rankings are based on publicly verifiable pricing, cancellation terms, FDA status, and editorial fit — not affiliate payout rates.

Quick comparison: 9 short term GLP-1 treatment providers scored on what actually matters

We compared every provider on the seven things that decide whether a “short-term” plan stays short-term — or quietly turns into a 12-month auto-renewal. Scores reflect fit for someone who specifically wants a 1-to-6-month plan, not overall provider quality.

How we scored: 25 points for billing structure (no subscription = highest), 20 for cancellation friction, 20 for clarity around what happens after month three, 15 for first-month value, 10 for compounded-vs-FDA-approved transparency, 10 for practical access (state availability, HSA/FSA, BNPL, insurance). Active FDA warning letters reduce the final score because they are material information for a reader making a YMYL medical and financial decision. Verified May 5, 2026.

We don’t take payment from providers in exchange for ranking. We do earn a commission when readers click through to some of these — disclosed throughout. We never claim a compounded medication has been “clinically proven” or is equivalent to a brand-name FDA-approved drug.

Should you even take a GLP-1 short-term? The honest medical answer

GLP-1 medications are designed as long-term obesity care, not as a 90-day cosmetic cut. Multiple major medical centers and peer-reviewed trials show that most people regain a significant share of lost weight within roughly 12 months of stopping. A defined-window plan (3 to 6 months) is something you can discuss with a clinician, but it works dramatically better when paired with an off-ramp plan you build before your first dose.

The hard truth most affiliate pages won’t tell you: when researchers at Yale, the University of Utah, MUSC, and Cleveland Clinic talk about how long someone should be on a GLP-1, they don’t say “3 months.” They say long-term, the same way doctors talk about blood pressure medication. The University of Utah Health team is direct: “GLP-1s are not meant for a short-term or cosmetic weight loss.” Cleveland Clinic explains that when you stop, hunger returns, food noise can return, and the biological drivers of weight regain reassert themselves.

The randomized data backs them up. The STEP 1 trial extension (Wilding et al., 2022) followed people who took semaglutide for 68 weeks and then stopped — at one year off the medication, participants had regained roughly two-thirds of the weight they had lost. The STEP 4 trial (JAMA, 2021) found the same direction: people who stopped semaglutide after the run-in period gained weight while those who continued lost more. The 2025 SURMOUNT-4 post-hoc analysis (tirzepatide withdrawal) and the 2026 Lancet eClinicalMedicine systematic review confirmed similar regain patterns across both drug classes.

But here’s the trust-building pivot: a defined-window plan can work if you go in with eyes open. The reader who beats the regain trajectory:

• Builds nutrition and resistance-training habits during the medication window
• Doesn’t quit cold turkey — talks to their provider about a step-down
• Asks the provider whether maintenance dosing makes sense
• Re-evaluates at month 6 instead of pre-committing to “stop forever”

The provider you pick matters less than the plan you build. We’ll show you both.

When a short-term GLP-1 plan actually makes sense (and when it doesn’t)

A 3-to-6-month GLP-1 trial is reasonable to discuss with a clinician if you have a clear bridge purpose, financial reality, or pre-event window — and unreasonable for cosmetic weight loss, undefined goals, or anyone with the medical contraindications below.

Reasonable reasons to consider a defined-window plan

• Financial reality. You can afford 3 months but not indefinite therapy. Better to start with a real plan than to wait.
• Coverage gap. You’re waiting on prior authorization, the next plan year, or the new Medicare GLP-1 Bridge (July 1 – December 31, 2027) for eligible Medicare Part D members.
• Pre-event or pre-surgical window. Wedding, reunion, surgery prep, military fitness test, structured pre-op weight loss requirement.
• Tolerability trial. You want to know if you can handle the medication before signing up for a year.
• Plateau-breaker after habit work. You’ve already done the lifestyle work and want medical support to break through.

When short-term GLP-1 is the wrong frame

• You want to lose 5 to 10 cosmetic pounds. GLP-1s are designed for adults with a BMI of 30+, or 27+ with a weight-related condition.
• You’re pregnant, breastfeeding, or planning to be in the next ~3 months.
• You have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. These are absolute contraindications.
• You have active or past pancreatitis, severe gastrointestinal disease, gastroparesis, or an active eating disorder. These need an in-person clinician.
• You’re managing complex diabetes medications. The combinations need real coordination.

If any of those apply to you, this isn’t the page for you — and we’d rather lose you to your primary care doctor than ship you to a telehealth provider who’ll prescribe over a 5-minute intake.

The 5 paths a short-term GLP-1 searcher can take

“Short term” is not one query — it’s five. The right provider depends on whether you want a true no-subscription pay-per-visit structure, FDA-approved medication with cancel-anytime billing, broad self-pay flexibility, FDA-approved with insurance help, or a needle-free niche format.

Which short-term GLP-1 providers are easiest to cancel?

Cancellation friction varies dramatically. Walgreens is the strictest “pay only when you visit” model — there’s nothing to cancel. Yucca Health’s published page says you can change or cancel treatment at any time. Eden’s compounded plan locks you into 3 prepaid months. Hims and Hers require 3-, 6-, 10-, or 12-month prepaid plans that are non-refundable after purchase — that structure is incompatible with short-term flexibility.

How much will 3 months of GLP-1 treatment really cost?

A truthful 3-month total depends on whether the medication is included in the price, whether there’s a separate membership fee, and whether the dose changes mid-program. Headline “as low as $X/month” prices almost always assume the longest prepaid plan — not the monthly cancel-anytime plan a short-term searcher actually wants.

Compounded providers with active FDA warning letters: what you should know

On February 20, 2026, the FDA issued warning letters to two compounded GLP-1 providers featured in many “best short-term” comparison pages: Fifty410 (warning letter #721481) and MEDVi (warning letter #721455). Both letters cited false or misleading marketing claims on the providers’ websites — specifically, language that implied FDA approval or evaluation of compounded products. The letters did not address medication safety, but they are material information for a reader making a YMYL medical and financial decision.

In March 2026, the FDA issued additional warning letters to more than 30 telehealth companies for similar marketing violations across the compounded GLP-1 industry. A warning letter is an enforcement communication, not a finding of guilt — companies have the opportunity to respond and correct cited issues, and many do successfully. But a reasonable short-term searcher needs to know this context before choosing.

The 4-step exit playbook: how to stop a GLP-1 without regaining everything

If you’re going to use a GLP-1 for a defined window, build this plan before your first dose — not after you decide to stop.

Step 1: Build lifestyle scaffolding during the medication window

The four things that predict post-GLP-1 weight maintenance better than the drug choice itself:

• Your protein target. Adequate protein helps preserve lean mass during weight loss. Your specific number depends on your body composition, activity level, and goals.
• Resistance training. GLP-1 weight loss includes some lean mass loss; resistance training is the most consistent way to mitigate it. Even 2-3 sessions a week makes a difference.
• Fiber and hydration. Both reduce GLP-1 GI side effects and build the satiety mechanisms that have to do the work after stopping.
• Sleep and stress. Both directly affect appetite hormones. The window where the medication is suppressing food noise is the easiest time to fix sleep and stress habits — don’t waste it.

Step 2: Don’t stop cold turkey — talk to your provider about a step-down

Before stopping, ask your prescribing clinician whether tapering, dose reduction, or a maintenance strategy is appropriate for your situation. Research published in 2025 (cited in the 2026 Lancet eClinicalMedicine systematic review) explored gradually reducing semaglutide doses to the minimum dose that maintains weight, rather than abrupt discontinuation. A typical step-down conversation might cover reducing to a lower maintenance dose for several months before stopping entirely.

Step 3: Ask whether maintenance dosing or a transition medication fits your case

Some providers offer a maintenance microdose protocol. The honest caveats:

• Microdose GLP-1 protocols are almost exclusively compounded (not FDA-approved), and long-term efficacy data is limited.
• Other transitions worth discussing with your clinician: metformin, naltrexone-bupropion, phentermine, or other obesity medications that may fit your situation better.

Step 4: Re-evaluate at month 6 — don’t pre-commit to “stop forever”

Here’s the reframe that changes everything: instead of “I’ll quit at month 6,” try “at month 6, I’ll evaluate weight stability, side effect tolerance, cost, and habit traction, and I’ll decide then.”

What to verify before paying any short-term GLP-1 provider (the 8-point checklist)

Eight items determine whether a short-term GLP-1 provider is genuinely flexible or quietly locks you in. Verify each one before you pay anyone — including the providers we recommend on this page. Use this on any provider page, not just the ones we list:

1. Is medication included or separate? Two providers can both quote “$199” — at one, that’s the medication; at the other, that’s just the membership.
2. What is the real monthly cost after the intro month? Ask the chat. Get it in writing.
3. What’s the cancellation notice? 72 hours? 21 days? Cancel via portal, or only by phone during business hours (a tell that retention is the real product)?
4. Are doses already shipped refundable under any condition? At most providers: no.
5. Does price increase as your dose escalates? Eden, MEDVi, Yucca, and Em lock the same price across doses. Some other providers don’t.
6. Is the medication FDA-approved or compounded? Both can be reasonable choices for the right patient — but you need to know which you’re getting.
7. Which pharmacy actually fills it? A 503A pharmacy is state-licensed for patient-specific compounding; a 503B outsourcing facility operates under stricter FDA oversight. “We don’t say” is not an answer.
8. What happens if you develop a side effect in week one? Confirm 24/7 messaging access, side effect support, and the dose-adjustment protocol before you have a problem.

We screenshot every provider page we cite, every 30 days, and update this article when material terms change.

Are these short-term GLP-1 providers available in your state?

State availability varies by provider and changes as licensing, regulations, and pharmacy partnerships shift. Here’s the quick snapshot:

• Available in most/all 50 states: Ro, GoodRx Care Direct, Walgreens, Sesame Care, Yucca Health, Em.
• Available in most states with some exclusions: Eden (excludes a small number of states for compounded plans — confirm at sign-up), Fifty410 (verify state-specific live-visit requirements), MEDVi (some states excluded).

If a provider doesn’t operate in your state, the matching quiz will route you to one that does.

Insurance, HSA/FSA, and the Medicare GLP-1 Bridge

Three things can dramatically change the cost of a short-term GLP-1 plan: insurance coverage, HSA/FSA eligibility, and the new Medicare GLP-1 Bridge demonstration.

If you have commercial insurance worth checking, run the coverage check first. Brand-name Wegovy and Zepbound retail at $1,300–$1,600/month without insurance. With insurance and a successful prior authorization, your cost can drop to a copay. Ro’s GLP-1 Insurance Coverage Checker is free, takes 30 seconds, and doesn’t require committing to anything.

HSA/FSA reimbursement is broader than most readers realize. Many GLP-1 program costs may be HSA/FSA eligible when medically necessary and properly documented. Verify with the provider and your account administrator before assuming reimbursement applies. See our HSA/FSA GLP-1 guide for which platforms accept HSA cards directly.

The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is the parallel demonstration for Medicaid, launching as early as May 2026. State Medicaid agencies must opt in, and CMS notes that the model “will not guarantee coverage for any individual.” Eligible drugs through BALANCE include all formulations of Mounjaro®, Ozempic®, Rybelsus®, Wegovy®, plus Foundayo and the Zepbound KwikPen.

Compounded vs FDA-approved: the line we never blur

Compounded GLP-1 medications and FDA-approved brand-name medications are different products with different regulatory standing. Compounded products are not FDA-approved finished drug products, are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro, and have not been reviewed by the FDA for safety, effectiveness, or quality as finished products.

FDA-approved brand-name GLP-1 medications include:

• Wegovy® (semaglutide injection and tablet — Novo Nordisk; tablet approved December 2025 for weight management)
• Zepbound® (tirzepatide injection — Eli Lilly; pen, vial, and KwikPen formulations)
• Foundayo™ (orforglipron tablet — Eli Lilly; FDA-approved April 1, 2026 for weight management)
• Saxenda® (liraglutide injection — Novo Nordisk)
• Ozempic® (semaglutide injection — FDA-approved for type 2 diabetes; sometimes prescribed off-label for weight loss when clinically appropriate)
• Mounjaro® (tirzepatide injection — FDA-approved for type 2 diabetes; sometimes prescribed off-label for weight loss when clinically appropriate)
• Rybelsus® (oral semaglutide — FDA-approved for type 2 diabetes)

The regulatory environment shifted significantly in 2025–2026:

• February 21, 2025: FDA removed semaglutide from the official drug shortage list.
• April 22 and May 22, 2025: Grace periods for shortage-era 503A and 503B compounding ended.
• 2026 ongoing: FDA continues to issue warning letters to telehealth companies for misleading claims about compounded GLP-1s — including the 30+ company action in March 2026.
• April 30, 2026: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Public comments are due by June 29, 2026.

A note on cited clinical trial data: Clinical trial data cited on this page (STEP 1, STEP 4, SURMOUNT-4, etc.) comes from FDA-approved medications studied in trials. These data should not be treated as proof that any compounded formulation will produce the same result.

Frequently asked questions about short-term GLP-1 providers

What we actually verified for this page

Verified May 5, 2026:

• Provider pricing pages and program terms (Ro, Eden, Yucca Health, MEDVi, Em, SHED, Sesame Care, Walgreens, GoodRx Care Direct, Fifty410)
• Cancellation, refund, and billing policies where publicly published
• FDA-approved medication availability per provider
• FDA Warning Letter database (specifically letter #721455 to MEDVi, LLC, and letter #721481 to Aspen Aesthetics dba Fifty 410, both dated February 20, 2026, available at fda.gov)
• FDA press release on the March 2026 30-company warning letter action
• CMS Medicare GLP-1 Bridge documentation
• CMS BALANCE Model documentation
• Peer-reviewed sources: STEP 1 trial extension (Wilding et al., 2022), STEP 4 (Rubino et al., JAMA 2021), SURMOUNT-4 post-hoc analysis (JAMA Internal Medicine 2025), 2026 Lancet eClinicalMedicine systematic review
• Medical authority sources: University of Utah Health, Cleveland Clinic, Yale Medicine, MUSC Health
• Public Trustpilot reviews and provider-published verified-patient quotes

Refresh cycle: This page is reviewed monthly for pricing changes, FDA enforcement updates, and policy changes. The “Last verified” timestamp at the top of the page reflects the most recent review.

The bottom line

Short-term GLP-1 use is not what the medical evidence recommends — but flexible, defined-window GLP-1 access is real, legitimate, and increasingly affordable. Nine providers offer credible short-term-friendly paths in 2026, each best for a specific situation:

• For most readers wanting FDA-approved medication with flexibility, Ro is the strongest fit — $39 first month, cancel anytime, lowest cash-pay branded prices, free insurance coverage check.
• For readers wanting the lowest-friction FDA-approved monthly subscription, GoodRx Care Direct’s $39/month telehealth fee plus FDA-approved medication starting at $149/month is the cleanest path.
• For readers wanting zero subscription at all, Walgreens at $49 per visit is the cleanest FDA-approved option.
• For readers wanting a familiar broad-menu telehealth platform with both compounded and brand-name options, Eden is the strongest in-network self-pay path.

If you’re going to use a GLP-1 for a defined window, the provider you pick matters less than the off-ramp plan you build before your first dose. Build the four-step exit playbook — lifestyle scaffolding, step-down conversation, maintenance options discussion, re-evaluate at month 6 — and a 3-to-6-month plan can work.

If you skip the playbook, the trial data says you’ll probably regain a meaningful share of the weight. We’d rather you know that going in than learn it the hard way.